<DOC>
	<DOCNO>NCT01050257</DOCNO>
	<brief_summary>This partially randomize , multi-center parallel-group study evaluate safety , pharmacokinetics effect viral load viral shed Tamiflu ( Oseltamivir ) patient influenza . Adult adolescent patient randomize receive either 100 mg 200 mg study drug intravenously every 12 hour . Investigators patient blind knowledge assign dose Tamiflu . There option convert oral Tamiflu 6 intravenous infusion . The anticipated time study treatment 5 day , optional treatment extension 5 day , necessary . There non-randomized , open-label treatment group patient moderate/severe renal impairment renal failure . Intravenous dose level frequency adjust appropriately renal situation .</brief_summary>
	<brief_title>A Study Intravenously Administered Tamiflu ( Oseltamivir ) Patients Over 13 Years Age With Influenza</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Adult adolescent patient , 13 year age old Diagnosis influenza â‰¤ 144 hour onset influenzalike illness first dose study drug Nonrandomized , openlabel treatment group : Patients moderate/severe renal impairment renal failure creatinine clearance 1060 mL/min Clinical evidence severe hepatic decompensation time randomization Acute ischemia significant arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>